Spongiform Encephalopathy Market Research Report- Global Forecast till 2030

Spongiform Encephalopathy Market Research Report Information By Type (Creutzfeldt Jakob, Vcjd, BSE, Scrapie, CWD), Diagnosis (Histopathology, Immunochemical Detection, Animal Bioassay, others), Treatment (Small Molecule, Immunotherapy), End User - Global Forecast till 2030

ID: MRFR/Pharma/3596-HCR | 85 Pages | Author: Rahul Gotadki | February 2024         

Spongiform Encephalopathy Market Speak to Analyst Request a Free Sample

Spongiform Encephalopathy Market Scenario


Spongiform encephalopathy market is expected to grow USD 549 Miillion at a CAGR 6.10% during the forecast period of 2023-2030. Transmissible Spongiform Encephalopathy (TSEs) is a group of neurodegenerative diseases that affect central nervous system (CNS) and more specifically the brain and spinal cord. In addition to humans, this condition also affects certain animal species such as sheep, goats, felines, mink, cattle, and deer. Transmissible spongiform encephalopathy is also known as prion disease, as prions are believed to be the causative agent of (TSEs). Prions are transmissible pathogenic agents that are able to induce abnormal folding of some normal cellular proteins i.e. prion proteins. Prion proteins are the most abundantly found in the brain. The most commonly known prion diseases in humans, are Fatal Familial Insomnia, Creutzfeldt-Jakob Disease (CJD), Gerstmann-Straussler-Scheinker Syndrome, and Kuru; most commonly identified animal prion diseases are Transmissible mink encephalopathy, Bovine Spongiform Encephalopathy (BSE), Scrapie, and others.


According to a study published in InTechOpen in 2017, it is found that in only 5 cases of BSE worldwide were reported in 2015, out of which, three were in Europe, one in Norway, and one in Canada. It is also reported that in the year 2016, two cases in France and Spain, and one in Ireland have been reported.


Various push factors such as, increasing awareness among people, increasing government assistance, and improvement in regulatory framework continuously contribute to the growth of the spongiform encephalopathy market.


However, challenges in research and development, and poor healthcare system in low and middle-income countries may hinder the growth of the Spongiform Encephalopathy Market to an extent over the review period.


Intended Audience



  • Pharmaceutical Companies

  • Veterinary Hospitals

  • Research and Development (R&D) Companies

  • Diagnostic Laboratories

  • Government Research Institute

  • Academic Institutes and Universities


Segmentation


The spongiform encephalopathy market is segmented on the basis of type, diagnosis, treatment, and end-user.


On the basis of the type, the market is segmented into in humans, in animals. The human's segment is classified into Creutzfeldt-Jakob disease, Variant Creutzfeldt-Jakob disease (vCJD), others. The others segment includes Gerstmann-Sträussler-Scheinker disease, fatal familial insomnia, and kuru (Papua New Guinea). The animals segment is classified into bovine spongiform encephalopathy (BSE), Scrapie in sheep and goats, Chronic Wasting Disease (CWD), Feline spongiform encephalopathy, others. BSE is further classified into classical BSE and atypical BSE.


On the basis of the diagnosis, the market is classified into histopathology and immunohistochemistry, immunochemical detection methods, animal bioassays, cell culture assay systems, protein misfolding cyclic amplification, conformation-dependent immunoassay, capillary electrophoresis, fluorescent correlation spectroscopy, multispectral ultraviolet fluorescence spectroscopy, and Fourier transform infrared spectroscopy. Histopathology and Immunohistochemistry are further segmented into immunohistochemical staining and electron microscopy. Immunochemical Detection Methods is further segmented into Western Blotting Test, and Enzyme-Linked Immunosorbent Assay (ELISA).


On the basis of the treatment, the market is classified into small molecules, and immunotherapies. The small molecules are further classified into pentosan polysulfate, quinacrine, amphotericin B, and others. Immunotherapies are further classified into Antibody-based immunotherapies and Cell-Based Immunotherapies. Antibody-based immunotherapies include passive immunization, active immunization, and targeting disease-specific epitopes. Cell-based immunotherapies include DC vaccines and adoptive transfer of CD4+ T-cells.


On the basis of the end-users, the market is segmented into hospital & clinics, diagnostic centers veterinary hospitals, research & academic laboratories, and others.


Regional Analysis


Europe dominates the spongiform encephalopathy market owing to the high prevalence of bovine spongiform encephalopathy in European region, support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe region


The Americas hold the second position in the spongiform encephalopathy market owing to the rising awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention, in 2015, the total health expenditure in the U.S. was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.


The Asia Pacific is the fastest growing spongiform encephalopathy market owing to the huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare, in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the year 2014-15.


The Middle East & Africa owns the least share of the spongiform encephalopathy market due to lack of technical knowledge and poor medical facilities.


Key Players


Some of key the players in the spongiform encephalopathy market are Teva Pharmaceuticals, Abbvie, Adamas Pharmaceuticals, Inc., Newron Pharmaceuticals SPA, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Lonza, Merck KGaA, Thermo Fisher Scientific Inc., and others.


Research Methodology Spongiform Encephalopathy Market


Sources: Annual reports, Press release, White paper, and Company presentation


 

Report Scope:

Report Attribute/Metric Details
  Market Size   USD 549 Miillion
  CAGR   6.10%
  Base Year   2022
  Forecast Period   2023-2030
  Historical Data   2021
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Diagnosis, Type, and Treatment
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors Pharmaceuticals, Abbvie, Adamas Pharmaceuticals, Inc., Newron Pharmaceuticals SPA, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Lonza, Merck KGaA, Thermo Fisher Scientific Inc., and others.
  Key Market Opportunities Increasing government assistance, and improvement in regulatory framework continuously contribute to the growth of the spongiform encephalopathy market.
  Key Market Drivers Awareness of the group of diseases among the masses is the major driver of the global spongiform encephalopathy market.




Frequently Asked Questions (FAQ) :

Spongiform encephalopathy market is expected to exhibit a CAGR of 6.10% from 2023 to 2030.

Awareness of the group of diseases among the masses is the major driver of the global spongiform encephalopathy market.

Lack of funds for research and development and poor healthcare systems in low and mid-income economies can restrain the global spongiform encephalopathy market growth.

Europe can lead the global spongiform encephalopathy market due to high cases of bovine encephalopathy in the region..

Teva Pharmaceuticals, Newron Pharmaceuticals SPA, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbvie, Merck KGaA, Lonza, Adamas Pharmaceuticals, Inc., and Abbott Laboratories are major players of the global spongiform encephalopathy market.

Key Questions Answered

  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players‚Äô financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample

Why Choose Market Research Future?

  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst
Leading companies partner with us for data-driven Insights.
Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid